Drawing for PHARMACAL

USPTO serial 75558563

PHARMACAL

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
FRENCH, CURTIS W
Law office
FILE REPOSITORY (FRANCONIA)

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with PHARMACAL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

COLIN P. ABRAHAMS

COLIN P ABRAHAMSGLENDALE FEDERAL BANK BLDG5850 CANOGA AVE STE 400WOODLAND HILLS, CA 91367

Goods and services

ClassDescriptionStatusFirst use
005pharmaceutical preparations for humans and veterinary preparations used to treat domestic pets and livestock, namely, biochemical compositions for the treatment of bone, connective tissue and teeth; compositions for reducing or eliminating bacterial plaque; compositions for controlling bacterial growth and colonization, particularly in the oral cavity; ligand-receptor molecules and compositions used in bone and connective tissue treatment; enzyme-anchor complexes for use in the treatment of bone and connective tissue, including such complexes where the enzyme is one or more of a hydrolase, esterase, glucosidase, and the anchor is one or more of a ligand, receptor, protein, protein fragment, saccharine, glycoprotein, proteoglycans, glycolipid, lipoprotein, and cell fragment; biochemical compositions bone enhancing and expediting the reformulation of bone tissue and connective tissue; enzymes, proteins, glycoproteins, ligands and receptors for bone and connective tissue treatment and reformulation; vitamin, mineral and nutritional supplements; biochemical and enzymatic compositions for treating blood, blood components and plasma; biochemical compositions for the treatment of ingested food to reduce the amount of cholesterol available for absorption from the digestive tract; compositions forming bone and connective tissue scaffolding, frames and/or extracellular matrices for use in bone and connective tissue reconstructionACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (ABN6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jul 9, 2001ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jan 8, 2001EX2GSOU EXTENSION 2 GRANTED—
Oct 12, 2000EXT2SOU EXTENSION 2 FILED—
Jun 7, 2000EX1GSOU EXTENSION 1 GRANTED—
Apr 11, 2000EXT1SOU EXTENSION 1 FILED—
Oct 12, 1999NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jul 20, 1999PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 18, 1999NPUBNOTICE OF PUBLICATION—
May 27, 1999CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 14, 1999CNEAEXAMINER'S AMENDMENT MAILED—
May 14, 1999DOCKASSIGNED TO EXAMINER—
Apr 26, 1999DOCKASSIGNED TO EXAMINER—
Apr 26, 1999DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance